BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22296608)

  • 1. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
    Pashov AI; Tskhay VB; Ionouchene SV
    Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
    Pronin SM; Novikova OV; Andreeva JY; Novikova EG
    Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.
    Nucera G; Mandato VD; Gelli MC; Palomba S; La Sala GB
    Gynecol Endocrinol; 2013 Mar; 29(3):219-21. PubMed ID: 23153053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
    Kresowik J; Ryan GL; Van Voorhis BJ
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
    Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
    Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservative treatment of early endometrial cancer: preliminary results of a pilot study.
    Laurelli G; Di Vagno G; Scaffa C; Losito S; Del Giudice M; Greggi S
    Gynecol Oncol; 2011 Jan; 120(1):43-6. PubMed ID: 21040953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
    Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
    Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
    Kim MK; Seong SJ; Lee TS; Kim JW; Nam BH; Hong SR; Suh KS
    Jpn J Clin Oncol; 2012 Dec; 42(12):1215-8. PubMed ID: 23071290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone therapy alone for pre-cancerous conditions and early endometrial cancer: pros and cons].
    Novikova OV; Andreeva IuIu; Novikova EG; Vostrov AN; Pronin SM; Rubtsova NA; Danilova NV; Lozovaia IuA; Podtetenev DV
    Vopr Onkol; 2014; 60(3):306-12. PubMed ID: 25033681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
    Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
    Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
    Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
    Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
    Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience].
    Ivanov S; Kovachev E; Tsonev A; Abbud A
    Akush Ginekol (Sofiia); 2010; 49(2):47-9. PubMed ID: 20734678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.